摘要弥漫性大B细胞淋巴瘤(dif use large B-cel lymphoma,DLBCL)是恶性淋巴瘤中最常见的类型之一,临床病理学上具有显著的异质性,主要体现在临床特点、组织形态、免疫表型、分子遗传学特征、生物学行为的复杂多样,还表现为治疗反应的不一致以及预后的差异性。本文就近年来弥漫性大 B细胞淋巴瘤的相关研究作一系统性回顾。
2Lossos IS,Jones CD,Warnke R,et al.Expression of a single gene,BCL-6,strongly predicts survival in patients with diffuse large B-cell lymphoma[J].Blood,2001,98(4):945-951.
3Bastard C,Deweindt C,Kerckaert JP,et al.LAZ3 rearrangements in non-Hodgkin's lymphoma:correlation with histology,immunophe notype,karyotype,and clinical outcome in 217 patients[J].Blood,1994,83(9):2423-2427.
4Rantanen S,Monni O,Joensuu H,et al.Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma[J].Leuk Lymphoma,2001,42(5):1089-1098.
5Colomo L,Lopez-Guillermo A,Perales M,et al.Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma[J].Blood,2003,101 (1):78-84.
6Iqbal J,Neppalli VT,Wright G,et al.BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma[J].J Clin Oncol,2006,24(6):961-968.
7Nyman H,Jerkeman M,Karjalainen-Lindsberg ML,et al.Bcl-2 but not FOXPI,is an adverse risk factor in immunochemotherapy- treated non-germinal center diffuse large B-cell lymphomas [J]. Eur J Haematol,2009,82(5):364-372.
8Adida C,Haioun C,Gaulard P,et al.Prognostic significance of survivin expression in diffuse large B-cell lymphomas[J].Blood,2000,96(5):1921-1925.
9Mainou-Fowler T,Overman LM,Dignum H,et al.A new subtypespecific monoclonal antibody for IAP-survivin identifies highrisk patients with diffuse large B-cell lymphoma and improves the prognostic value of Bcl-2[J].Int J Oncol,2008,32(1):59-68.
10Hasselblom S,Ridell B,Sigurdardottir M,et al.Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma[J].Leuk Lymphoma,2008,49(8):1501-1509.
